Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $314.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price boosted by Bank of America from $307.00 to $314.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price objective points to a potential upside of 9.27% from the company’s current price.

Other analysts also recently issued reports about the company. Raymond James lifted their price objective on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. UBS Group boosted their price target on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a report on Friday, June 28th. BMO Capital Markets reissued an “outperform” rating and issued a $234.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Stifel Nicolaus upped their target price on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 30th. Six research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $285.95.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $287.36 on Monday. The firm’s 50-day moving average is $269.96 and its 200 day moving average is $214.43. The stock has a market cap of $36.35 billion, a price-to-earnings ratio of -107.22 and a beta of 0.39. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $289.67.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same quarter in the previous year, the business posted ($2.21) EPS. Alnylam Pharmaceuticals’s revenue was up 107.0% on a year-over-year basis. On average, equities analysts expect that Alnylam Pharmaceuticals will post -2.73 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,829,070. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,148 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at $19,829,070. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,398 shares of company stock worth $13,595,460. 1.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. V Square Quantitative Management LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after buying an additional 287,064 shares in the last quarter. SteelPeak Wealth LLC lifted its position in shares of Alnylam Pharmaceuticals by 147.7% during the 1st quarter. SteelPeak Wealth LLC now owns 6,860 shares of the biopharmaceutical company’s stock worth $1,025,000 after buying an additional 4,090 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares in the last quarter. Finally, Quattro Financial Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 2,517.8% during the 1st quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock worth $747,000 after buying an additional 4,809 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.